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Abstract 
OBJECTIVE: The objective of this selective evidence based medicine review is to determine 
whether or not far infrared therapy reduces the incidence of arteriovenous fistula (AVF) 
malfunction in patients with renal disease undergoing hemodialysis. 
STUDY DESIGN: Review of three primary randomized controlled trial studies published from 
2007-2013. 
DATA SOURCES: Three peer-reviewed randomized controlled trials studying the effectiveness 
of far infrared therapy in the preservation of native arteriovenous fistula function in patients with 
chronic kidney disease requiring hemodialysis. Data searches done in PubMed, CINAHL Plus 
and EBSCOhost. 
OUTCOMES MEASURED: Primary outcome measured was episodes of AVF malfunction due 
to stenotic complication. After randomization, patient outcomes were monitored and recorded 
over the span of 12 months to assess the effectiveness of far infrared therapy at preventing AVF 
malfunction. AVF malfunction was defined as any stenosis-related change in the AVF resulting 
in blood flow rate <200 ml/min (which requires surgical intervention or angioplasty). Infection, 
aneurysm formation and steal syndrome were not considered stenosis-related.  
RESULTS: All three articles demonstrated a lower incidence of AVF malfunction in patients 
treated with far infrared therapy. The studies in question demonstrated zero incidence of any 
adverse effect.  
CONCLUSIONS: This review reinforces the author’s conclusions that FIR therapy, a non-
invasive technique, is a useful modality for the prevention of complications requiring surgical 
intervention and the preservation of arteriovenous fistulas. These conclusions should not be 
extrapolated to patients with artificial AV grafts.  
KEY WORDS: far infrared therapy; arteriovenous fistula; hemodialysis 
 
 
 
 
 
 
 
Barrett – FIR Therapy and Hemodialysis  1 
 
Introduction 
Malfunction of vascular access is the most common cause of increased morbidity and 
need for hospital admission in patients receiving hemodialysis.
5
 A technique capable of 
extending the life of a vascular access port without complication would have potential to 
improve the lives of the millions of people who require dialysis, as well as save the US an 
estimated billion dollars in health care costs annually.
4
 This paper evaluates three recent RCTs 
which address the efficacy of far-infrared therapy at reducing the incidence of stenosis related 
arteriovenous fistula (AVF) malfunction.  
AVF’s are commonly the first choice for vascular access patients with stage 3 or 4 kidney 
disease because they are the access method with the lowest rates of infection and clotting 
problems.
5
 The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 
National Institutes of Health (NIH) estimates 398,861 ESRD patients were being treated with 
some form of dialysis in 2009. Being a Physician Assistant in the ED, primary care, internal 
medicine, surgery, nephrology and probably others will require knowledge of kidney dialysis and 
the treatment mechanisms currently available to this patient population. 
The estimated annual cost of vascular access related morbidity to the US is $1 billion 
dollars.
4
 The exact number of healthcare visits each year is not known, but according to the NIH, 
at the end of 2009, more than 871,000 people were being treated for ESRD, 398,861 of which 
were receiving dialysis.  
AVF malfunction remains the biggest obstacle to maintaining successful hemodialysis. 
The most common source of complication is stenosis and/or thrombosis at the site of the AVF, 
which alters flow state.
5
 Hemodialysis access fistulas alter fluid flow patterns within the vessel. 
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Hemodialysis also requires frequent cannulation of the AVF. Over time, intimal hyperplasia 
occurs secondary the frequent irritation by cannulation and in areas of turbulent blood flow, 
which is generally at the created anastomosis. Hyperplasia results in decreased patency and 
further alteration of flow pattern. Decreased flow through the area can then result in thrombosis 
and eventual occlusion. A specific flow rate (>200 ml/min) is required for adequate 
hemodialysis. These intravascular conditions synergistically create an environment prone to 
complication. It is important to prevent complications interfering with hemodialysis for the 
obvious reason that without adequate hemodialysis access, patients with end stage renal disease 
cannot receive the treatment allowing for their survival and must shift to alternate forms of 
dialysis with greater inherent risk of infection.  
There is no currently accepted or widely used therapy which prevents the formation of 
intimal wall lesions and subsequent complications at the AVF site.
6
 Problems arising from 
thrombosis and stenosis of the AVF are dealt with as they arise, which typically involves either 
stent placement or angioplasty depending on the preference of the physician.
6 
Far infrared (FIR) therapy is a non-invasive technique that is being proposed as a means 
to prevent complications at the AVF site and thus sustain AVF patency. It entails the 
administration of electromagnetic wavelengths via an external transmitter. Treatment involves 
placing a radiator device above the surface of the AVF for a period of minutes several times per 
week. Far infrared therapy can be done while undergoing hemodialysis treatments. Intervention 
specifics are listed in Table 1.  
Authors suggest administration of FIR therapy improves endothelial function and 
prevents pathogenic changes associated with increased risk of AVF malfunction. Specifically, 
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the therapy has vasodilatory effects, prevents intimal hyperplasia, decreases oxidative stress and 
suppresses inflammation.
2
 Thus, a therapy such as this could reduce morbidity and cost 
associated with AVF complications. 
Objective 
 The objective of this selective EBM review is to determine whether or not far infrared 
therapy is an efficacious way to reduce the incidence of stenosis-related AVF malfunction in 
patients receiving hemodialysis. 
Methods 
 Articles designated for this selective evidence based medicine review have proven to be 
adequate to investigate the objective. The articles consist of three randomized control trials. The 
articles were selected using the key words:  far infrared therapy; arteriovenous fistula (AVF); 
hemodialysis. The author of this selective EBM review, Parker Barrett, conducted the research in 
Cochrane, PubMed, CINAHL Plus and EBSCOhost in January 2014. All articles were published 
in Chinese and English languages in peer-reviewed journals. Articles were chosen if they 
assessed patient oriented outcomes and included patients with CKD requiring hemodialysis, 
patients with native AVF, and population age greater than 18. Articles were excluded if they 
were review articles, non-patient oriented outcomes, and population age less than 18. Statistics 
were reported using p-values, relative risk reduction (RRR), absolute risk reduction (ARR), 
numbers needed to treat (NNT). P-values less than 5% were considered statistically significant. 
 In Lin et al. (2013)
3
, a prospective randomized controlled trial, inclusion criteria were 
patients 18-80 years old with CKD and eGFR = 5-20 mL/min/1.73m
2
, recently created upper 
extremity venous-to-arterial anastomosis and patients not anticipated to receive dialysis or renal 
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transplant within three months. FIR therapy was initiated 2 days postoperative anastomosis 
creation 3 times weekly for 12 months. Before starting hemodialysis, 40 minutes of FIR was 
done 3 times weekly at home or clinic. After beginning dialysis, FIR therapy was done for 40 
minutes 3 times weekly during hemodialysis at clinic. External far infrared therapy (via FIR 
emitter) set at a height of 25 cm above the surface of the AVF. 
In Lin et al. (2007)
1
 and  Lin et al. (2013)
2
, both prospective randomized controlled trials, 
the inclusion criteria were identical and as follows: patients receiving 4 hours hemodialysis 3 
times weekly for at least 6 months via upper extremity venous-to-arterial anastomosis, in patients 
without interventions within the past 3 months. FIR therapy was done for 40 minutes 3 times 
weekly during hemodialysis at clinic for 12 months. External far infrared therapy (via FIR 
emitter) set at a height of 25 cm above the surface of the AVF.  
The demographics of the studies included are demonstrated in Table 1. All three studies 
used untreated control groups for comparison. Patients were censored (withdrawal in Table 1) for 
reasons other than AVF malfunction, i.e. those with renal transplant, death with a functioning 
access, shift to peritoneal dialysis for reason other than stenotic complication, loss to follow up 
or non-stenotic complications (infection, aneurysm, steal syndrome). 
Randomization accounted for differences in patient comorbidities. All three studies 
compared clinical characteristics of FIR treated and control groups, including age, gender, the 
length of time since AVF creation, history of AVF malfunction, and prevalence of hypertension 
and diabetes. Statistical analysis showed no significant difference between the two groups in all 
cases (p-values > 5%).  
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Outcomes Measured 
Outcomes measured included number of episodes of AVF malfunction secondary to 
stenotic complication. After randomization, patient outcomes were monitored and recorded over 
the span of 12 months to assess the effectiveness of FIR therapy at reducing the incidence of 
stenotic AVF malfunction. AVF malfunction was defined as any stenosis-related change in the 
AVF resulting in blood flow rate <200 ml/min (which requires surgical intervention or 
angioplasty). Infection, aneurysm formation and steal syndrome were not considered stenosis-
related.  
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Table 1: Demographics and Characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion criteria Exclusion 
Criteria 
W/D Intervention 
 Lin, 
2007
1 
RCT  145 18-80 (i) receiving 4 h of 
maintenance HD 
therapy 3 times weekly 
for at least 6 months 
(ii) using a native AVF 
as the present vascular 
access 
for >6 months, without 
interventions within last 
3 months 
(iii) creation of AVF by 
venous-to-arterial 
anastomosis in upper 
extremity 
 
AV graft as 
the first 
vascular 
access. 
18 Far-infrared radiation 
via emitter set at a 
height of 25 cm 
above the surface of 
the AVF for 40 min 
during hemodialysis 
3 times per week. 
Lin, 
2013
2 
RCT 280 18-80 (i) receiving 4 h of 
maintenance HD 
therapy 3 times weekly 
for at least 6 months 
(ii) using a native AVF 
as the present vascular 
access 
for >6 months, without 
interventions within last 
3 months 
(iii) creation of AVF by 
venous-to-arterial 
anastomosis in upper 
extremity 
AV graft as 
the first 
vascular 
access. 
34 Far-infrared radiation 
via emitter set at a 
height of 25 cm 
above the surface of 
the AVF for 40 min 
during hemodialysis 
3 times per week. 
Lin, 
2013
3
  
RCT 122 18-80 (i) CKD and eGFR = 5-
20 mL/min/1.73m2 
(ii) Recently created 
upper extremity venous-
to-arterial anastomosis 
(iii) Patients not 
anticipated to receive 
dialysis or renal 
transplant within three 
months 
AV graft as 
the first 
vascular 
access. 
14 Far-infrared radiation 
via emitter set at a 
height of 25 cm 
above the surface of 
the AVF for 40 min 
during 3 times per 
week (during 
hemodialysis once it 
has begun) 
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Results 
 All three studies compared FIR therapy to untreated control groups and thus data 
breakdown was experimental vs. untreated. All relevant data was presented in dichotomous 
form, easily assessed for treatment effect on complication incidence. Figure 1 depicts the raw 
incidence of stenosis-related AVF malfunction over the span of 12 months in all three studies. 
All three studies showed zero incidence of adverse effect, such as skin burn or allergy to therapy.  
 
Lin et al., 2007
1
 demonstrated a statistically significant reduction in AVF malfunction 
incidence (P<0.01), with 12.5% (9/63) of FIR treated patients and 30.1% (22/64) of untreated 
patients developing new AVF malfunction. Absolute risk reduction was calculated as 17.6%, 
while the NNT was calculated as 6 (Table 2). Relative risk reduction was found to be 58.5%. 
This suggests a 17.6% reduction in stenotic complication incidence and that 6 patients must be 
treated with FIR therapy to prevent one AVF malfunction. The relative risk reduction indicates a 
58.5% reduced risk of stenotic malfunction in FIR treated patients.  
 
Figure 1: Incidence of AVF Malfunction within 12 Months
9
22
15
33
7
18
0
5
10
15
20
25
30
35
FIR therapy Control
Lin 2007 (source 1)
Lin 2013 (source 2)
Lin 2013 (source 3)
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Lin et al. 2013
2
 observed a statistically significant reduction in stenotic AVF malfunction 
incidence, with 12.6% (15/119) of FIR treated patients and 27.5% (33/120) of untreated patients 
developing new AVF malfunction (p = 0.004). Absolute risk reduction was calculated as 14.9%, 
while the NNT was calculated as 7 (Table 2). Relative risk reduction was found to be 54.2%. 
This suggests a 14.9% reduction in stenotic complication incidence and that 7 patients must be 
treated with FIR therapy to prevent one AVF malfunction. The relative risk reduction indicates a 
54.2% reduced risk of stenotic malfunction in FIR treated patients. 
Table 2: Efficacy of FIR Therapy in Reducing the Incidence of AVF Malfunction 
 p-value RRR ARR NNT 
Lin et al., 2007
1 <0.01 0.585 0.176 6 
Lin et al. 2013
2 0.004 0.542 0.149 7 
Lin et al. 2013
3 0.02 0.586 0.170 6 
 
Lin et al. 2013
3
 observed a statistically significant reduction in stenotic AVF malfunction 
incidence, with 12% (7/60) of FIR treated patients and 29 % (18/62) of untreated patients 
developing new AVF malfunction (p = 0.02). Absolute risk reduction was calculated as 17.0%, 
while the NNT was calculated as 6 (Table 2). Relative risk reduction was found to be 58.6%. 
This suggests a 17.0% reduction in stenotic complication incidence and that 6 patients must be 
treated with FIR therapy to prevent one AVF malfunction. The relative risk reduction indicates a 
58.6% reduced risk of stenotic malfunction in FIR treated patients. 
Discussion 
Native arteriovenous fistulae are the most superior form of vascular access for 
hemodialysis, due to lower infection rates and greater durability.
5
 AVF failure necessitates other 
access modalities with higher risk for infection and subsequent sepsis, making preservation of 
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the native fistula of the utmost importance.
5
 Far infrared therapy is a non-invasive technique 
which could potentially be a useful modality for the prevention of thrombotic complications 
requiring percutaneous or surgical declotting and the preservation of native arteriovenous 
fistulas. 
The precision of statistical values across the three studies (Table 2), consistent study 
parameters, and adequate sample sizes speak well in support of the authors conclusions.  
Few of the current approaches to preventing AVF thrombosis are supported by statistical 
efficacy. Neither antiplatelet therapy nor systemic anticoagulation has proven to be effective in 
thrombosis prevention.
6
 Avoidance of unnecessary venipuncture and fish oil (4 g per day) are the 
only current measures routinely recommended for prevention of AVF thrombosis.
6
 Stenosis is 
generally addressed as it becomes apparent with percutaneous angioplasty. Considering the low 
number of currently available preventative techniques and the lack of apparent adverse effects, 
FIR therapy could prove to be a beneficial adjunct to hemodialysis.  
Sample sizes were adequate for analysis of statistical significance. Compliance was 100% 
due to the fact that FIR treatment was tied to hemodialysis. Study limitations include the lack 
blinding in the control group. Blinding for future studies would require the use of a sham device 
similar in appearance to the FIR transducer. Despite lack of sham, results suggest efficacy 
beyond that of the placebo effect.  
The most concerning limitation of the results listed above is the singular institution and 
authors responsible for the conduction of all three studies. Lin and colleagues of the Yang-Ming 
University of Taiwan have put forth excellent data, but reproduction by unaffiliated colleagues is 
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necessary. Also, all study participants were native to the region, so investigation as to whether 
ethnicity has any effect on treatment outcome is desirable. 
Little investigation has been done into the cost of making far infrared therapy available at 
hemodialysis facilities, or any form of cost-benefit analysis for that matter. A formal 
investigation into the annual cost of stenotic AVF malfunction vs. the savings allowed for by 
making far infrared therapy available on a large scale is needed. 
Conclusion 
The data assessed in this EBM review suggest far infrared therapy does significantly 
reduce the incidence of arteriovenous fistula malfunction in patients undergoing hemodialysis. 
Patients receiving FIR therapy required fewer interventions in all three studies. Further research 
is needed to determine if the reduction of complication incidence can be extended to patients 
with graft AVF ports. Reproduction of effects by another group of researchers would also be 
desirable.  
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